Abbott touts dorsal root ganglion stim study

Abbott (NYSE:ABT) today touted short- and long-term data published in the journal Pain, which demonstrated that its dorsal root ganglion stimulation therapy benefits patients suffering from complex regional pain syndrome more than traditional spinal cord stimulation. The Abbott Park, Ill.-based company said it’s the only company in the world approved to offer DRG stimulation. The newly-published data is from the company’s ACCURATE study, which evaluated DRG stimulation in patients for 3 and 12 months. “Historically, many patients with chronic pain resulting from complex regional pain syndrome or pain resulting from damage to peripheral nerves report inconsistent or inadequate pain relief from tonic spinal cord stimulation. As a physician this is frustrating because our ultimate goal is to deliver options providing meaningful pain relief,” lead author Dr. Timothy Deer said in prepared remarks. “The findings highlighted in our publication align with what I’ve seen in my practice since U.S. approval of DRG stimulation: that DRG stimulation offers a superior option for CRPS-related chronic pain and improved quality of life for my patients.” After 3 and 12 months, patients who received Abbott’s DRG stimulation therapy had meaningful pain relief and 74.2% of them had treatment success, compared to 53% of patients who received traditional SCS. Secondary endpoint data showed that at 12 months, more than a third of the patients who re...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Pain Management Research & Development Spinal Abbott Source Type: news